Verbatim response from Perplexity
Several telehealth brands appear to still offer compounded GLP-1s as of the recent FDA crackdown, but the most important caveat is that the FDA has been issuing warning letters specifically for false or misleading marketing, not announcing a blanket ban on every telehealth compounding arrangement.[2][4][5]
Brands mentioned in recent reporting as still in this market include Lovely Meds, Hello Cake, and MEDVi.[4] That same reporting says these companies are among more than 70 telehealth companies warned by the FDA, and that many of them rely on affiliated medical groups such as Beluga Health, OpenLoop, MD Integrations, and Telegra to handle prescribing.[4]
A practical way to think about the landscape is:
- Still active in compounded GLP-1 telehealth: Lovely Meds, Hello Cake, MEDVi[4]
- Affiliated infrastructure often behind the scenes: Beluga Health, OpenLoop, MD Integrations, Telegra[4]
- Under FDA scrutiny for marketing claims: telehealth companies broadly, including the 30 firms named in the FDA’s warning-letter action[2]
Important nuance: the FDA materials you provided focus on marketing and claims around compounded semaglutide/tirzepatide, not a simple public list of “approved telehealth sellers.”[1][2] Because telehealth availability can change quickly after warning letters, the safest check before buying is whether the service is still taking new GLP-1 patients, which pharmacy it uses, and whether it is offering compounded versus FDA-approved medication.